Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

Abstract

Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided. Embodiments provided herein encompass isotopologues of Compound A and pharmaceutically acceptable salts, stereoisomers, tautomers, solid forms, polymorphs, hydrates, clathrates, and solvates thereof.

What is claimed is: 
     
         1 . A compound, wherein the compound is an isotopologue of a compound having the following structure: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, stereoisomer, polymorph or solvate thereof. 
     
     
         2 . The compound of  claim 1 , wherein the isotopologue is an isotopologue of a compound having the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound of  claim 1 , wherein the isotopologues are deuterium-enriched. 
     
     
         4 . The compound of  claim 1 , wherein the isotopologue is a compound having the formula: 
       
         
           
           
               
               
           
         
         wherein one or more of Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , Y 12 , Y 13 , Y 14 , Y 15 , Y 16 , Y 17 , Y 18 , Y 19 , Y 20 , Y 21 , and Y 22  is a hydrogen that is isotopically enriched with deuterium, and the others of Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , Y 12 , Y 13 , Y 14 , Y 15 , Y 16 , Y 17 , Y 18 , Y 19 , Y 20 , Y 21 , and Y 22  are non-enriched hydrogen atoms. 
       
     
     
         5 . The compound of  claim 4 , wherein one of Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , Y 12 , Y 13 , Y 14 , Y 15 , Y 16 , Y 17 , Y 18 , Y 19 , Y 20 , Y 21 , and Y 22  is isotopically enriched with deuterium, and the others are non-enriched hydrogens. 
     
     
         6 . The compound of  claim 4 , wherein two of Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , Y 11 , Y 12 , Y 13 , Y 14 , Y 15 , Y 16 , Y 17 , Y 18 , Y 19 , Y 20 , Y 21 , and Y 22  are isotopically enriched with deuterium, and the others are non-enriched hydrogens. 
     
     
         7 . The compound of  claim 4 , wherein the compound is: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         8 . A pharmaceutical composition comprising a compound of  claim 1 , or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         9 . A method of treating, managing or preventing a disease or disorder comprising administering to a patient a compound of  claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein the disease or disorder is cancer, cardiovascular disease, inflammatory disease, autoimmune disease or a metabolic disorder.